Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer

New England Journal of Medicine

Volumn 379, Issue 21, 2018, Pages 2040-2051

  Paz Ares, L ^a   Luft, A ^c   Vicente, D ^b   Tafreshi, A ^d   Gumus M ^e   Mazieres J ^g   Hermes, B ^h   Cay Senler F ^f   Csoszi T ⁱ   Fulop A ^j   Rodriguez Cid J ^k   Wilson, J ^l   Sugawara, S ^m   Kato, T ⁿ   Lee, K H ^o   Cheng, Y ^p   Novello, S ^q   Halmos, B ^r   Li, X ^s   Lubiniecki, G M ^s   Piperdi, B ^s   Kowalski, D M ^t   more..

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^c Leningrad Regional Clinical Hospital   (Russian Federation)

^d Wollongong Oncology and Wollongong Private Hospital   (Australia)

^e ISTANBUL MEDENIYET UNIVERSITY   (Turkey)

^f ANKARA UNIVERSITY   (Turkey)

^g TOULOUSE UNIVERSITY HOSPITAL   (France)

^h UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

ⁱ Jász Nagykun Szolnok County Hospital   (Hungary)

^j Orszagos Koranyi Tbc es Pulmonologiai Intezet   (Hungary)

^k Medica Sur Hospital   (United States)

^l HUMBER RIVER REGIONAL HOSPITAL   (Canada)

^m SENDAI KOUSEI HOSPITAL   (Japan)

ⁿ KANAGAWA CANCER CENTER   (Japan)

^o Chungbuk National University Hospital   (South Korea)

^p JILIN CANCER HOSPITAL   (China)

^q UNIVERSITY OF TURIN   (Italy)

^r ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^s MERCK RESEARCH LABORATORIES   (United States)

^t INSTITUTE OF ONCOLOGY   (Poland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ATEZOLIZUMAB; CARBOPLATIN; IPILIMUMAB; PACLITAXEL; PEMBROLIZUMAB; PLACEBO; PROGRAMMED DEATH 1 RECEPTOR; SODIUM CHLORIDE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADD ON THERAPY; ADULT; AGED; ALOPECIA; ANEMIA; ARTHRALGIA; ARTICLE; ASTHENIA; AUTOIMMUNE HEPATITIS; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; COLITIS; CONSTIPATION; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; FOLLOW UP; HEPATITIS; HUMAN; HYPERTHYROIDISM; HYPOPHYSITIS; HYPOTHYROIDISM; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHRITIS; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; SKIN MANIFESTATION; SQUAMOUS CELL LUNG CARCINOMA; THROMBOCYTOPENIA; THYROIDITIS; VERY ELDERLY; VOMITING; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; INTENTION TO TREAT ANALYSIS; LUNG TUMOR; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; NON SMALL CELL LUNG CANCER; SECONDARY; SURVIVAL ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTENTION TO TREAT ANALYSIS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; PROGRAMMED CELL DEATH 1 RECEPTOR; PROGRESSION-FREE SURVIVAL; SURVIVAL ANALYSIS;

EID: 85054684704     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1810865     Document Type: Article

References (25)

1. Lortet-Tieulent J, Soerjomataram I, Ferlay J, Rutherford M, Weiderpass E, Bray F. International trends in lung cancer incidence by histological subtype: ad-enocarcinoma stabilizing in men but still increasing in women. Lung Cancer 2014; 84:13-22.
2. Cheng TY, Cramb SM, Baade PD, Youl-den DR, Nwogu C, Reid ME. The international epidemiology of lung cancer: latest trends, disparities, and tumor characteristics. J Thorac Oncol 2016;11:1653-71.
3. Soldera SV, Leighl NB. Update on the treatment of metastatic squamous non-small cell lung cancer in new era of personalized medicine. Front Oncol 2017;7: 50.
4. Socinski MA, Obasaju C, Gandara D, et al. Current and emergent therapy options for advanced squamous cell lung cancer. J Thorac Oncol 2018;13:165-83.
5. Thatcher N, Hirsch FR, Luft AV, et al. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. Lancet Oncol 2015;16:763-74.
6. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015;373:123-35.
7. Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2016; 387:1540-50.
8. Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 2016;375: 1823-33.
9. Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 2017;389:255-65.
10. Lopes G, Wu Y-L, Kudaba I, et al. Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥1%: open-label, phase 3 KEYNOTE-042 study. J Clin Oncol 2018;36:Suppl:LBA4. abstract.
11. Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 2018;378:2078-92.
12. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, eds. AJCC cancer staging manual. 7th ed. New York: Springer, 2010.
13. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55.
14. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.
15. Roach C, Zhang N, Corigliano E, et al. Development of a companion diagnostic PD-L1 immunohistochemistry assay for pembrolizumab therapy in non-small-cell lung cancer. Appl Immunohistochem Mol Morphol 2016;24:392-7.
16. Cutica I, Vie GM, Pravettoni G. Per-sonalised medicine: the cognitive side of patients. Eur J Intern Med 2014;25:685-8.
17. Carbone DP, Reck M, Paz-Ares L, et al. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. N Engl J Med 2017;376:2415-26.
18. Govindan R, Szczesna A, Ahn MJ, et al. Phase III trial of ipilimumab combined with paclitaxel and carboplatin in advanced squamous non-small-cell lung cancer. J Clin Oncol 2017;35:3449-57.
19. Jotte RM, Cappuzzo F, Vynnychenko I, et al. IMpower131: primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC. J Clin Oncol 2018;36:Suppl: LBA9000. abstract.
20. Hellmann MD, Ciuleanu TE, Pluzan-ski A, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med 2018;378:2093-104.
21. Borghaei H, Hellmann MD, Paz-Ares LG, et al. Nivolumab (nivo) + platinum-doublet chemotherapy (chemo) vs chemo as first-line (1L) treatment (Tx) for advanced non-small cell lung cancer (NSCLC) with <1% tumor PD-L1 expression: results from CheckMate 227. J Clin Oncol 2018; 36:Suppl:9001. abstract.
22. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015; 372:2018-28.
23. Langer CJ, Gadgeel SM, Borghaei H, et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol 2016;17:1497-508.
24. Brahmer J, Rodriguez-Abreu D, Robinson A, et al. Updated analysis of KEYNOTE-024: pembrolizumab vs platinum-based chemotherapy for advanced NSCLC with PD-L1 TPS ≥50%. J Thorac Oncol 2017;12:Suppl 2:S1793. abstract.
25. Borghaei H, Langer CJ, Gadgeel S, et al. 24-Month overall survival from KEYNOTE-021 cohort G: pemetrexed and carboplatin with or without pembrolizumab as first-line therapy for advanced nonsquamous non-small-cell lung cancer. J Thorac Oncol 2018 August 20 (Epub ahead of print).